These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21288201)

  • 1. Special edition myeloproliferative neoplasia - disease pathogenesis and treatment options.
    Wolf D; Rumpold H
    Curr Cancer Drug Targets; 2011 Jan; 11(1):1-2. PubMed ID: 21288201
    [No Abstract]   [Full Text] [Related]  

  • 2. Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?
    Barosi G; Tefferi A; Barbui T;
    Leukemia; 2012 May; 26(5):1148-9. PubMed ID: 22105597
    [No Abstract]   [Full Text] [Related]  

  • 3. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
    James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
    Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Myelodysplastic/myeloproliferative neoplasia: a diagnostic and therapeutic challenge].
    Benz R
    Ther Umsch; 2022; 79(2):107-113. PubMed ID: 35291846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder.
    Townsend W; Cross NC; Waghorn K; Somana K; Ramsay A; Thomson K; Peggs K
    Bone Marrow Transplant; 2009 Aug; 44(3):197-9. PubMed ID: 19234514
    [No Abstract]   [Full Text] [Related]  

  • 6. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.
    Loscocco GG; Mannelli F; Guglielmelli P; Paoli C; Marone I; Cucci R; Coltro G; Sordi B; Albano F; Breccia M; De Stefano V; Finazzi G; Iurlo A; Martino B; Palandri F; Passamonti F; Siragusa S; Mannelli L; Fantoni D; Fazi P; Amadori S; Vignetti M; Barbui T; Vannucchi AM
    Am J Hematol; 2019 Sep; 94(9):E239-E242. PubMed ID: 31179561
    [No Abstract]   [Full Text] [Related]  

  • 7. Focus on myeloproliferative diseases and myelodysplastic syndromes.
    Van Etten RA; Shannon KM
    Cancer Cell; 2004 Dec; 6(6):547-52. PubMed ID: 15607959
    [No Abstract]   [Full Text] [Related]  

  • 8. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
    Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
    Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic myeloproliferative disorders: from molecular physiopathology to clinical presentation].
    Dan K
    Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1329-30. PubMed ID: 17682416
    [No Abstract]   [Full Text] [Related]  

  • 10. The mosaic of myeloid neoplasia: implications for classification.
    Steensma DP
    Leuk Lymphoma; 2008 Jul; 49(7):1228-9. PubMed ID: 18604710
    [No Abstract]   [Full Text] [Related]  

  • 11. European Working Group (EWG) meeting on myeloproliferative disorders (MPDDs).
    Brière J
    Pathol Biol (Paris); 2004 Jun; 52(5):265-6. PubMed ID: 15217711
    [No Abstract]   [Full Text] [Related]  

  • 12. A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease.
    Loscocco GG; Mannelli F; Mannelli L; Vergoni F; Gesullo F; Rotunno G; Guglielmelli P; Vannucchi AM
    Am J Hematol; 2020 Dec; 95(12):1622-1624. PubMed ID: 32242958
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
    Levine RL; Pardanani A; Tefferi A; Gilliland DG
    Nat Rev Cancer; 2007 Sep; 7(9):673-83. PubMed ID: 17721432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for JAK2 mutations in myeloproliferative diseases.
    Morgan KJ; Gilliland DG
    Annu Rev Med; 2008; 59():213-22. PubMed ID: 17919086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in biological and therapeutic aspects of myeloproliferative disorders.
    Mancini M; Diverio D; Alimena G; Mandelli F
    Curr Opin Hematol; 1994 Jul; 1(4):261-7. PubMed ID: 9371292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases].
    Hrubisko M
    Vnitr Lek; 2011 Feb; 57(2):138-9. PubMed ID: 21416852
    [No Abstract]   [Full Text] [Related]  

  • 17. Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer.
    Raskind WH; Steinmann L; Najfeld V
    Leukemia; 1998 Feb; 12(2):108-16. PubMed ID: 9519769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary myeloproliferative disorders.
    Skoda RC
    Haematologica; 2010 Jan; 95(1):6-8. PubMed ID: 20065077
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
    Macdonald D; Cross NC
    Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recommendations for the cytogenetic management of myeloproliferative syndromes proposed by the French Group for Cytogenetic Hematology].
    Groupe Français de Cytogénétique Hématologique (GFCH)
    Pathol Biol (Paris); 2004 Jun; 52(5):241-4. PubMed ID: 15217703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.